471 patents
Page 10 of 24
Utility
Time to Resolution of Axitinib-related Adverse Events
2 Jun 22
This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment.
Despoina Thomaidou
Filed: 30 Nov 21
Utility
PHOSPHATIDYLINOSITOL-3-KINASE Pathway Biomarkers
2 Jun 22
Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting tile presence or absence in a patient of one or more of PIK3CA gene amplification a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tifrosine kinase inhibitor.
Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
Filed: 9 Nov 21
Utility
d4skvbbrz8hkztjja8fby23ugboyxeyh88ae54fwbdzclt62wjq1
2 Jun 22
In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof.
Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
Filed: 15 Feb 22
Utility
qne9 8lc2nbufva5duo37s239xbguzapbfili8hb0cy4xz
26 May 22
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Alexey Vyacheslavovitch Gribenko, Nicholas Randolph Everard Kitchin, Paul Liberator, Michael William Pride, Christopher Frederick Webber
Filed: 30 Mar 20
Utility
w22kmoueghr0c90uvlm3xnb8og4ap6e
12 May 22
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof.
Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
Filed: 21 Jan 22
Utility
52wtzy0ez9bja439rell7h52q667n5p9v663w0yudxmz0ufi0usr7ubrw0
12 May 22
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 17 Dec 21
Utility
3xej8dykmcyt22bx45rhn6fdz t7qcl4ck
12 May 22
The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
Xiaojing YANG, Amanda Patrice Surajhie SAMUEL
Filed: 12 Feb 20
Utility
2srwbvxqnz82fk02a0to35yuh mzlfy003x7ngi37dzlvtvj5
5 May 22
The present invention relates to the treatment of chronic low back pain with an anti-nerve growth factor (NGF) antibody.
Christine Ruth WEST, Mark Thomas BROWN, Candace Roskoph BRAMSON
Filed: 14 Feb 20
Utility
ux1crfrg1auhrborhu68952uyolr7k2 wa8
5 May 22
The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
Ling Chu, Scott Andrew Cook, Nishith Merchant, Justin Keith Moran
Filed: 20 Feb 20
Utility
ufqu159a8au8yb0mrkqy8d9gqlfy 70f0gvirnxm
28 Apr 22
This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.
Zhou Zhu, Yuan Liu
Filed: 31 Jan 20
Utility
ecgjcg1g2oh pwzwo16qxmp
28 Apr 22
Douglas Carl Behenna, Martha Alicia Ornelas
Filed: 13 Jan 20
Utility
g0ox7lt0vqowgx6 8o6mjtp692gxnrehnleyklm4ab
28 Apr 22
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.
Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
Filed: 10 Jan 22
Utility
c3wkhdq2ytwh4880ug8i87o261yr0pwdd35cy8swy9ue7ide4 6y9n89j
21 Apr 22
In one aspect, the invention relates to use of a composition including a first polypeptide and a second polypeptide, wherein the composition elicits an immune response against Neisseria meningitis serogroup B strains expressing, for example, variants A02, A28, A42, A63, A76, B05, B07, B08, B13, B52 and B107.
Annaliesa Sybil Anderson, Paul Liberator, Thomas Richard Jones, Kathrin Ute Jansen, John Lance Perez, Shannon Lea Harris
Filed: 7 Feb 20
Utility
70xjtdr6975 ocqg9uudah8xm0hoxwie9e8
21 Apr 22
Steven W. ANDREWS, James F. BLAKE, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, David A. MORENO, Li REN, Shane M. WALLS
Filed: 29 Oct 21
Utility
u5caunv1spe0 05d0njp4q6v
21 Apr 22
The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM.
Karin Anderson
Filed: 4 Jun 21
Utility
lpw3bkxrt445ynp 33r11dvemhktn60m656nxhcpb6i6lp6t7ibizj
21 Apr 22
The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.
Lewis C. CANTLEY, Stephen P. SOLTOFF, Brooke M. EMERLING, George POULOGIANNIS, Cindy M. HODAKOSKI, Hui LIU, Irina APOSTOLOU, Brian Gaither BATES, Kimberly Ann MARQUETTE, Eric M. BENNETT, Lidia MOSYAK, Lioudmila G. TCHISTIAKOVA, Edward Christian ROSFJORD, Isaac J. RONDON, Chao Bai HUANG
Filed: 7 Nov 19
Utility
h67tpuk0c2wwy2l0u7u8hxldfxsd0d8a
14 Apr 22
Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided.
Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
Filed: 7 Oct 21
Utility
vwe7koyiqgjj1wjk8jjc9hnb5pnchb0ulxe04tnzs upfdi31r9
14 Apr 22
James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Dean KAHN, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Ginelle A. RAMANN, Li REN, Shane M. WALLS, Hailong ZHANG
Filed: 6 Sep 19
Utility
9k3oyi1t3f05gt1c5hiei 5rz3l05n3a
31 Mar 22
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
Filed: 5 Aug 21
Utility
h5uz1h5s7ecr1d dyyaz
24 Mar 22
Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
Filed: 7 Dec 21